Andrew has almost 30 years industry experience, having worked in large multinational pharmaceutical companies, global and regional contract research organizations, the biotech sector, as well as other service providers. He brings a global approach, having gained international experience during appointments in the USA, Japan and throughout Europe.
Andrew joined Optimapharm’s executive management team in July 2020 following several months advising the company’s Board of Directors.
Andrew holds a PhD in Respiratory & Exercise Physiology from Loughborough University, UK and a Bachelor Degree (Hons) in Applied Biology from East London University, UK. He is also a Fellow of the Royal Society of Medicine.
Gordana has held the position of Chief Operating Officer at OPTIMAPHARM since July 2020, and is responsible for leading the Company’s operations and for securing high functionality and performance of Clinical Operations, Clinical Project Management and Regulatory & Safety Departments.
Gordana founded OPTIMAPHARM in 2006 and performed the CEO function for 14 years, growing the company from SEE regional niche player to mid-sized, full-service European CRO.
Prior to that, Gordana excelled in both Clinical Project Management and Senior Management positions within leading global (Ingenix, i3 research) and international CRO companies (Ergomed, SAR Monitoring Services), including regional and country business responsibilities. She was also a Board Member at the Ingenix Pharmaceutical Services (i3 research) in Croatia.
Gordana graduated from the School of Medicine at the University of Zagreb in 1995. In 2001, she completed postgraduate studies in Clinical Pharmacology and Toxicology.
Walter has over 25 years industry experience, with demonstrated capabilities in fast growing companies, having worked in several international biotech companies and European CRO. As CFO he was responsible for Corporate Finance, Legal, IT, HR as well as the Risk Management, Compliance and Corporate Governance. Prior to that, Walter hold several senior manager positions in Finance and Operations. He has led and worked on various international projects related to financing/IPO, financial due diligence, valuation projects as well as M&A and in- and out-licensing activities.
From December 2020 onwards Walter took over responsibility as Chief Financial Officer at Optimapharm.
Walter holds a Master of Science in Economics from University of Applied Sciences in Aachen, Germany, a Bachelor of Arts in Studies of Sciences on Marriage and Family from MEDO International Academic Institute for Studies on Marriage and Family, Kerkrade, Netherlands and holds a controller‘s-diploma from the Controller Akademie in Gauting, Germany.
Anamaria graduated from the School of Pharmacy and Biochemistry, University of Zagreb. She has over 16 years of international clinical research experience in the fields of Clinical Operations and Clinical Project Management covering various therapeutic areas but with special expertise in oncology, CNS and metabolic diseases.
In 2008, Anamaria joined OPTIMAPHARM’s team, obtaining different roles in the company: sCRA, Clinical Project Manager, Country Manager and Clinical Project Management Director.
In 2020, she assumed the role of Vice President Clinical Project Management and is responsible for the management, strategic planning, development and execution of all Clinical Project Management activities.
Anamaria is actively involved in the development of various company training programs, company quality activities and internal organizational management projects.
Mirna is a finance expert with extensive experience in investment banking, controlling, and finance management. Her career started in the investment banking division of Intesa Sanpaolo PBZ.
Mirna has worked on many industry and company analyses, company valuations, business planning and M&A transactions gaining valuable experience in financial modeling, strategic planning and market research.
Later, she was responsible for setting up the controlling department in a regional commercial bank, working closely with the Management and Supervisory Board on strategic planning, ALM, external audits and investor relations. In 2012, Mirna joined Optimapharm's team.
Igor has 20 + years of track record in investment banking, executive management and private equity investments. He is the founder of Optimapharm and has maintained a significant minority equity position after TRG investment in Optimapharm in 2020. From 2011 until 2020, Igor served as Chairman of the Supervisory Board and he was strongly involved in realization of the impressive growth of the company during that period.
Igor is the Founder of Provectus Capital Partners, the growth capital investor in SME businesses in Adriatic region. Provectus Capital Partners helped create and now advises Adriatic Structured Equity Fund (ASEF Sc sp). ASEF is a Luxemburg based PE fund providing capital and financing solutions to established mid-market businesses.
Prior to that, Igor performed different senior executive positions within the corporate and banking sector in Croatia.
Igor graduated at Faculty of Economics and Business in Zagreb, has completed GMP program in Vienna and Senior Executive Program at London Business School.